Magnetic resonance imaging improves breast cancer diagnosisMarch 29, 2007International study shows a detection rate higher than 90 percent Women who have been diagnosed with breast cancer in one breast have a higher risk of contracting the disease in their opposite breast as well. A thorough examination of the opposite breast using mammography and ultrasound is therefore common practice. However, many tumours still remain undetected when using mammography. Magnetic resonance imaging (MRI) promises better results, as is shown in an inter-national study involving the University of Bonn. In almost 1,000 women with a recent diagnosis of breast cancer in one breast, MRI helped identify 30 cancers in the seemingly normal opposite breast . In women with a normal (negative) MRI of the opposite breast, there was a 99.6% confidence that in fact no breast cancer was present — which means that if the MRI study is normal, preventive mastectomy of the opposite breast, which some women want, is definitely unnecessary . These findings have now been published in the prestigious journal "New England Journal of Medicine." About two dozen sites in North America participated in the study, as well as one sole site outside the USA, the University of Bonn. Bonn was selected as a team member due to its internationally leading position in breast cancer diagnostics. A total of 968 patients were examined, almost 200 of them at the University of Bonn alone. "Therefore, proportionally, most patients came from our Department, which means that the data from Bonn had a substantial impact on the results of the entire study," explains Professor Christiane Kuhl from the Department of Radiology of the University of Bonn. All the women had previously been diagnosed with tumours in one breast. A mammography as well as a clinical examination of the opposite breast had remained normal and without evidence of breast cancer . The patients then underwent breast MRI .Using MRI, the doctors found tumours in the other breast in as many as 30 women, yielding a contralateral cancer yield of over 3%-which is a high rate given the fact that regular breast cancer screening yields a detection rate of around 1 per million.. "It is already well established that an MRI is essential before breast cancer surgery in order to delineate the extent of the disease and provide a road map for the surgeon. Now we know that it is also important for discovering further tumours in the opposite breast which was presumed to be healthy," Professor Kuhl says.
What is particularly reassuring for women with a recent diagnosis of breast cancer is that if the doctors did not discover a tumour on MRI, there was a 99.6% certainty that the breast indeed was free of cancer. "A prophylactic mastectomy of the opposite breast, which some patients want, is definitely unnecessary if an MRI shows no evidence of cancer," she emphasises. Although the MRT is comparatively expensive, "it is definitely the most reliable method that is currently available for diagnosing breast cancer. Breast MRI should be considered the standard of care for screening women who carry an increased risk of breast cancer — be it due to a strong family history, or, as our results show, due to a recent diagnosis of supposedly unilateral breast cancer," she says. "And women themselves should be aware of this." University of Bonn | |||||||||||||||||||||
|
Related Breast Cancer News Articles M. D. Anderson study finds change in HER2 status after treatment with Herceptin Researchers at The University of Texas M. D. Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. M. D. Anderson study finds racial disparities in radiation therapy rates for breast cancer Black women are less likely than white women to receive radiation therapy after a lumpectomy, the standard of care for early stage breast cancer, according to a new study by researchers at The University of Texas M. D. Anderson Cancer Center. New nano device detects immune system cell signaling Scientists have detected previously unnoticed chemical signals that individual cells in the immune system use to communicate with each other over short distances. CSHL scientists identify new drug target against virulent type of breast cancer Tumor cells in a particular subset of breast cancer patients churn out too much of a protein called ErbB2 -- also often called HER2 -- which drives the cells to proliferate unchecked. Patients unlucky enough to be in this group -- about one in four -- have poorer prognoses and clinical outcomes than those who don't. Dense tissue promotes aggressive cancers New research may explain why breast cancer tends to be more aggressive in women with denser breast tissue. Breast cancer cells grown in dense, rigid surroundings step up their invasive activities, Vanderbilt-Ingram Cancer Center investigators report in the Sept. 9 issue of Current Biology. Women exposed to negative life events at greater risk of breast cancer: BGU study Happiness and optimism may play a role against breast cancer while adverse life events can increase the risk of developing the disease. Hormone replacement therapy improves sleep, sexuality and joint pain in older women One of the world's longest and largest trials of hormone replacement therapy (HRT) has found that post-menopausal women on HRT gain significant improvements in quality of life. Positive thinking may protect against breast cancer Feelings of happiness and optimism play a positive role against breast cancer. Research published today in the open access journal BMC Cancer suggests that while staying positive has a protective role, adverse life events such as the loss of a parent or close relative, divorce or the loss of a spouse can increase a woman's risk of developing the disease. Anti-tumor effects are enhanced by inhibiting 2 pathways rather than 1 Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that still need to be answered. Why a common treatment for prostate cancer ultimately fails Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences. More Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||